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Abstract
Objective—To examine differences in maternal characteristics and pregnancy outcomes between 
women with ovulatory dysfunction (OD) and women with tubal obstruction (TO) who underwent 
assisted reproductive technology (ART).
Design—Retrospective cohort study.
Setting—Centers for Disease Control and Prevention.
Patient(s)—Exposed and nonexposed groups were selected from the 2000–2006 National ART 
Surveillance System linked with live-birth certificates from three states: Florida, Massachusetts, 
and Michigan.
Intervention(s)—None.
Main Outcome Measure(s)—Maternal characteristics and pregnancy outcomes, including 
newborn’s health status right after delivery (Apgar score, <7 vs. ≥7) as the study outcome of 
interest, were assessed among women with OD/polycystic ovary syndrome (PCOS) and TO who 
used ART.
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Result(s)—A significantly higher prevalence of women with OD/PCOS were younger (<35 
years of age; 65.7% vs. 48.9%), were white (85.4% vs. 74.4%), had higher education (29.4% vs. 
15.6%), and experienced diabetes (8.8% vs. 5.3%) compared with those having TO. The odds of 
having a lower (<7) Apgar score at 5 minutes were almost twice as high among newborns of 
women with OD/PCOS compared with those with TO (crude odds ratio, 1.86; 95% confidence 
interval [CI], 1.31, 2.64; adjusted odds ratio, 1.90; 95% CI, 1.30, 2.77).
Conclusion(s)—Women with OD/PCOS who underwent ART have different characteristics and 
health issues (higher prevalence of diabetes) and infant outcomes (lower Apgar score) compared 
with women with TO.
Keywords
Ovulatory dysfunction (OD); polycystic ovary syndrome (PCOS); tubal obstruction (TO); assisted 
reproductive technology (ART); Apgar score
As defined by the International Committee for Monitoring Assisted Reproductive 
Technology and the World Health Organization, “infertility is a disease of the reproductive 
system defined by the failure to achieve a clinical pregnancy after 12 months or more of 
regular unprotected sexual intercourse” (1, 2). Worldwide, nearly 72.4 million couples 
experience fertility problems, with an incidence similar in most countries and independent of 
the level of the country’s development (3). According to 2006–2010 data from the National 
Survey of Family Growth (NSFG), in the United States, an estimated 6% of married women 
ages 15–44 years are infertile, and an estimated 11.9% (7.4 million) of women from the 
same age group have ever received infertility services (4). An estimated infertility 
prevalence of 15.5% was found in both married and cohabiting women 15–44 years of age 
by a recent study that used the same survey (NSFG) and a different novel current duration 
approach (5).
Infertility can have many causes and may be related to factors in the male, female, or both. 
In some cases, each partner may be independently fertile but the couple cannot conceive 
together without assistance (i.e., unexplained infertility) (6, 7). Risk behaviors and 
environmental exposure may also influence the ability to conceive (8).
One of the two most prevalent causes of female infertility is ovulatory dysfunction (OD), 
characterized by an impaired hormone profile that may have an impact on women’s health 
beyond and during pregnancy, assisted reproductive technology (ART) response, and 
pregnancy outcomes, including the offspring’s health. Chronic OD (i.e., oligo-ovulation, 
anovulation) is most commonly caused by polycystic ovary syndrome (PCOS), which is 
known for its hyperandrogenism, and disordered gonadotropin secretion (LH 
hypersecretion), which is often associated with insulin resistance (9–12). The syndrome, 
which modulates both hormonal and metabolic processes, is the most common 
endocrinopathy in reproductive-age women and increases women’s risk of infertility, 
cardiometabolic disease, and endometrial pathology (i.e., endometrial cancer) (13). PCOS is 
defined by any two of the following: clinical/ biochemical hyperandrogenism, OD, and 
polycystic ovaries (14, 15). PCOS most likely encompasses several distinct diseases with 
similar clinical phenotypes but different underlying pathophysiological processes. However, 
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hyperandrogenism remains the syndrome’s clinical hallmark (13–15). The estimated 
prevalence of PCOS is between 6% and 10% based on the National Institutes of Health 
criteria and as high as 15% when the broader Rotterdam criteria are applied (14, 15). Its 
etiology remains obscure, and there is variability in phenotype expression, with evidence of 
a genetic component found in family and twin studies (16). When achieving pregnancy, 
women with PCOS have a significantly higher risk of developing gestational diabetes, 
pregnancy-induced hypertension, eclampsia, and preterm birth. The existing evidence 
suggests that PCOS has a life span pathway with two dimensions, horizontal (impact on 
women’s health over time) and vertical (effects in offspring of women with PCOS shortly 
after delivery and over time due to fetal exposure to hyperandrogenism that might disturb 
epigenetic programming, in particular those genes regulating reproduction and metabolism) 
(16–18).
Conversely, tubal obstruction (TO), also known as tubal factor infertility, the second most 
common cause of female factor infertility, is a mechanical factor. Most commonly, tubes are 
obstructed owing to infection such as pelvic inflammatory disease (PID), with the rate of 
obstruction increasing after each episode of PID (8). Other infections that might occlude or 
disable the tubes include infections after childbirth or abortions and intra-abdominal 
infections including appendicitis and peritonitis. The hormone profile of women with TO 
alone should be relatively normal, assuming no impact on ovarian function due to previous 
surgeries or inflammation.
For over three decades, ART has been used in the United States to help women overcome 
infertility. The Centers for Disease Control and Prevention (CDC) has conducted 
surveillance on the use, efficacy, and outcomes of ART treatments in the United States since 
1995 (19, 20). To promote state-based surveillance of ART and infertility, CDC’s Division 
of Reproductive Health, in collaboration with the Florida Department of Health (FDOH), 
Massachusetts Department of Public Health (MDPH), and Michigan Department of 
Community Health (MDCH), formed the States Monitoring ART (SMART) Collaborative. 
SMART provides a unique opportunity for federal and state public health agencies to work 
together from linking the information from ART surveillance with state data (live births, 
infant and fetal deaths, other surveillance systems and registries) to conducting research. 
Thus far, this collaborative has focused on data validity and agreement, impact of ART on 
maternal health and pregnancy outcomes, and related trends. The linked files that have been 
created have not yet been used to assess the impact of different infertility diagnoses, 
independently of ART, on pregnancy characteristics and outcomes. As more linkages are 
performed, more information will be available and thus more studies may be designed with 
the scope of exploring and understanding infertility within the context of prior overall health 
of the reproductive-age population.
This paper examines the differences in maternal characteristics and pregnancy outcomes, 
including newborns’ health immediately after birth, between women with the two most 
prevalent female-specific infertility diagnoses, OD and TO, who underwent ART procedures 
in the three states participating in the SMART Collaborative.
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We used the National ART Surveillance System (NASS) data linked with state live-birth 
records for the years 2000–2006 from Florida, Massachusetts, and Michigan and a 
retrospective cohort study design.
NASS is a web-based ART data collection system supported by the Division of 
Reproductive Health at CDC. The Fertility Clinic Success Rate and Certification Act of 
1992 requires that all clinics performing ART provide data to the CDC annually for all 
initiated cycles during that year (20). NASS data cover >95% of ART cycles performed in 
the United States annually and include detailed information on each ART procedure 
(primarily IVF) performed during the reporting year (19). NASS contains information on 
reasons for performing each reported ART cycle (infertility diagnosis), which was used for 
the current analysis. The information on each ART procedure was collected from ART 
clinics by the Society for Assisted Reproductive Technology for the years 2000–2003 and 
by Westat for the years 2004–2006.
Data were linked with the three states’ birth certificate files at CDC by using the CDC-
developed software LinkPlus and a probabilistic linkage algorithm that led to identification 
of the live births resulting from ART (21). Maternal date of birth, infant date of birth, 
plurality, gravidity, and maternal resident ZIP codes by state were used as link factors. 
Ancillary variables used to solve questionable linkages included maternal race, infant birth 
weight, and infant sex. The linking success rates were 89.6 for Massachusetts, 90.1 for 
Florida, and 92.3 for Michigan. Two validation studies assessed the accuracy of the 
probabilistic linkage method and found high sensitivity and specificity (22).
Using the NASS female infertility diagnosis variables, we were able to limit our study to 
female-specific infertility, more specifically to women with only one of the following 
diagnoses: OD only (exposed) or TO only (nonexposed). There were no missing values in 
these variables. Women with PCOS make up the majority of the OD group (23); therefore, 
for the remainder of the study we will refer to women having ovulatory disorders as OD/
PCOS and to those having tubal obstruction as TO. We also restricted the study to only the 
first successful ART delivery/birth for women identified as having multiple deliveries to 
thus focus on the study objectives and eliminate the potential impact of subsequent 
treatments on maternal complications and pregnancy outcomes.
The first part of the study focused on exploring the differences in selected maternal and 
pregnancy characteristics and in pregnancy outcomes including the newborn’s immediate 
health between women with OD/PCOS (considered exposed to impaired hormone profile) 
and those with TO (considered nonexposed given the likelihood that this group has a normal 
hormone profile). Descriptive statistics were used, and percentages with their respective 
95% confidence intervals (CIs) were reported.
The selected maternal and pregnancy characteristics, pregnancy outcomes, and newborn 
characteristics originated from the state live-birth records and included maternal age (<35 
years; ≥35 years), race/ethnicity (white, black, Hispanic, other), education (high school 
degree and less, some college/college graduate, more than college), adequacy of prenatal 
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care (Kotelchuck index categories, ≥adequate, adequate, intermediate, and inadequate), 
comorbid conditions (preexisting hypertension, gestational hypertension, and diabetes that 
included both gestational and preexisting), delivery method (vaginal or cesarean section), 
induction of labor (yes or no), plurality (singleton, twins, and ≥triplets), gestational age at 
birth (<37 and ≥37 completed weeks gestation), birth weight (<2,500 and ≥2,500 g), 
pregnancy outcome (derived using a composite variable of gestational age and birth weight 
<37 completed weeks gestation and <2,500 g; ≥37 weeks gestation and ≥2,500 g), newborn 
sex (female or male), Apgar score at 5 minutes (<7 or ≥7), and neonatal intensive care unit 
(NICU) admission (yes or no). The last two variables were selected as measures of a 
newborn’s health. The Apgar score, developed by Dr. Virginia Apgar, is a simple and 
repeatable method to quickly assess the newborn’s health immediately after birth and to 
record fetal-to-neonatal transition, despite its limitations in preterm infants (24–26). NICU 
admission is often used as an indirect measure of the health status of preterm and low birth 
weight infants. Unfortunately, there was inconsistency in the reporting of this variable 
during the study period (Florida reported it from 2004) and therefore a high percentage of 
missing values.
In the second part of the study, we examined the impact of infertility diagnosis (impaired 
hormone profile in OD/PCOS compared with in TO) on the outcome of interest that was 
identified through bivariate analysis (crude odds ratios [cORs] and corresponding 95% CIs) 
of pregnancy outcomes and infant characteristics. With the intention to eliminate the impact 
of multiple pregnancies, and especially deliveries, on pregnancy outcomes and newborn 
characteristics, we restricted the analysis to only singletons and first-order multiples.
The association between OD/PCOS and the outcome of interest was explored further 
through multivariable analysis (logistic regression). The multivariable model was adjusted 
for maternal age, race, education, adequacy of prenatal care per the Kotelchuck index, 
comorbidities (hypertension and diabetes), method of delivery (vaginal and cesarean 
section), labor induction, composite gestational age and birth weight as pregnancy outcome, 
and infant’s sex. Adjusted odds ratio (aOR) and 95% CI were reported for the outcome of 
interest.
SAS software version 9.2 and SAS callable SUDAAN version 10.0 (RTI International) were 
used for data analyses.
The project was approved by the Institutional Review Boards of CDC, FDOH, MDPH, and 
MDCH.
RESULTS
During 2000–2006, 16,876 women from Florida, Massachusetts, and Michigan underwent 
ART procedures that resulted in a live birth. Of these, 8.5% (n = 1,433) had infertility due to 
OD/PCOS only and 19.5% (n = 3,294) due to TO only.
Differences were observed between women with these two infertility diagnoses. 
Specifically, a significantly higher percentage of women with OD/PCOS were young (<35 
years; 65.7%), white (85.4%), and more educated (more than college; 29.4%) compared 
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with women with TO (48.9%, 74.4%, and 15.6%, respectively). The prevalence of diabetes 
was significantly higher (8.8%) in women with OD/PCOS as compared with in women with 
TO (5.3%; Table 1). A significantly higher percentage of newborns of women with OD/
PCOS had an Apgar score at 5 minutes that was below 7 (3.0%) compared with those born 
to women with TO (1.6%; Table 2).
In contrast, the prevalence of hypertension (preexisting and gestational) was not 
significantly different among women with OD/PCOS (31.3% and 33.6%, respectively) 
compared with those with TO (39.2% and 40.0%, respectively; Table 1). Also, no 
significant differences were found in adequacy of prenatal care, method of delivery and 
labor induction (Table 1), and pregnancy outcomes such as gestational age, birth weight, 
composite variable of the two, infant’ sex. and NICU admissions (Table 2).
Bivariate analysis of selected pregnancy outcomes and infant characteristics of women with 
OD/PCOS compared with those with TO confirmed a significant difference between the two 
infertility groups in their respective Apgar scores at 5 minutes (<7 or ≥7; Table 2). Apgar 
score was therefore selected as the outcome of interest.
Multivariable modeling and analysis (logistic regression) revealed that the difference in 
Apgar score at 5 minutes remained statistically significant after controlling for maternal age, 
race, education, adequacy of prenatal care, comorbidities, method of delivery, labor 
induction, composite gestational age and birth weight, and infant’s sex. Specifically, the 
odds of having an Apgar score <7 at 5 minutes was almost twice as high among newborns of 
women with OD/PCOS compared with among newborns of women with TO (Table 3).
DISCUSSION
The prevalence of OD/PCOS that was not associated with other infertility diagnoses among 
women from Florida, Massachusetts, and Michigan who underwent ART from 2000 through 
2006 was 8.5%. It mirrors prior reports of PCOS prevalence among women of reproductive 
age (6%–10%) (14, 15). However, it is an underestimate of the true prevalence, given that 
only women who had OD/PCOS as their sole infertility diagnosis were counted. If we had 
included women with PCOS in conjunction with other causes of infertility, we would report 
the prevalence of PCOS as 11.7%.
When comparing women with OD/PCOS with those with TO, significant differences were 
found in the prevalence of certain maternal demographics, specifically age, race/ ethnicity, 
and education. The difference in age between the two groups may be partially explained by 
women with OD/ PCOS seeking infertility treatment earlier than their counterparts with TO 
owing to their ability to conceive spontaneously later in life. This is known as delayed fertile 
window in women with PCOS since there is a tendency to have regular menstrual cycles 
with advancing age (27). The high prevalence of white women in the OD/PCOS group 
compared with in the TO group is consistent with findings from other studies suggesting that 
ethnic origin and culture may contribute to the differing manifestation of infertility including 
PCOS (28). The race/ ethnic difference has also been highlighted at the European Society of 
Human Reproduction and Embryology/American Society for Reproductive Medicine–
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sponsored Third PCOS Consensus Workshop that was held in 2010 (15). The high levels of 
education among women with OD/PCOS may reflect differences in socioeconomic status.
The significantly higher prevalence of diabetes found in our study among women with OD/
PCOS compared with those having TO has been previously described (14, 15, 18). 
However, our study did not confirm some of the previously identified characteristics of 
women with PCOS, such as gestational hypertension (12, 17). The prevalence of multiple 
and preterm births were similar between women with OD/PCOS and women with TO, and 
no significant differences were observed in NICU admission rates, which are in contrast 
with other prior findings (29). The discrepancies that were found are likely due to the nature 
of our study population, which included only women who underwent ART, thus controlling 
for the procedure’s impact on these particular characteristics and outcomes that may be 
stronger than those of the hormone profile alone, which was considered as exposure in our 
study.
The nonsignificant difference in low birth weight infants between the two infertility groups 
were found in other studies that suggested the possible impact the exposure to elevated 
androgen levels may have on a PCOS phenotype but with no impact on birth weight (30).
The significantly higher odds of lower Apgar score (<7) at 5 minutes in newborns of women 
with OD/PCOS reported by our study mirrors the findings of prior studies that explored the 
impact of PCOS on pregnancy outcomes and newborns (17, 29). Lower Apgar score within 
the context of a nonsignificant difference in NICU admission may reflect only a transient 
inability of newborns of women with OD/PCOS to adjust to the extrauterine environment 
due to abnormalities in placental steroidogenesis or other unknown reasons. This hypothesis 
is, in part, supported by the findings of a clinical study that measured and reported mixed 
cord blood T, androstenedione (A), dehydroepiandrosterone,17-hydroxyprogesterone, E2, 
and dihydrotestosterone in newborns of women with PCOS compared with those hormone 
levels in the newborns of women with normal hormone profiles. In that study, the female 
offspring of women with PCOS were found to have lower cord blood A levels and E2 levels 
that suggested decreased fetal or placental production of steroids due to an abnormality in 
placental steroidogenesis (31, 32). Despite being sex specific (female) and based on cord 
blood measurements that are not ideal for evaluation of prenatal androgen exposure, these 
findings may possibly explain the poor response of newborns of mothers with PCOS to 
labor and delivery stress and later to adjustment to the external environment, which are all 
reflected in a low Apgar score with or without admission to the NICU. Other explanations of 
the findings are, however, possible (29).
Unfortunately there are limited population-level data on PCOS available, and that could be 
the reason for limited penetration of the prior clinical study findings into the public health 
arena. The same limited penetration had the evidence related to familial aggregation of 
hormonal abnormalities in a study of first-degree relatives of women with PCOS and/ or the 
findings related to siblings of women with PCOS, including males, predisposed to hormonal 
abnormalities typical of PCOS (33–35). The increasing interest in linking clinical aspects 
with public health as well as in the knowledge related to fetal programming and familial 
aspects of chronic diseases set the perfect stage for improving the population-level 
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information on PCOS. Thus reproductive age–specific syndromes like PCOS may be 
incorporated within the priorities focused on chronic disease prevention and health 
promotion. Furthermore and perhaps the most important argument for the need for better 
data on and monitoring of PCOS for effective prevention strategies and public health actions 
is the high cost associated with this syndrome that has been estimated based on the 
knowledge gained thus far. For instance, given an estimated 4 million women of 
reproductive age (15–44 years) with PCOS in the United States (6.6% estimated 
prevalence), the annual economic burden is at least $4.36 billion. This estimate does not 
consider the greater frequency of pregnancy-related complications including gestational 
diabetes, preeclampsia, and miscarriage. Of note, the cost of the diagnostic evaluation 
accounted for a relatively minor part of the total costs (approximately 2%). Therefore, more 
widespread and liberal screening for the disorder appears be a cost-effective strategy, 
leading to earlier diagnosis and interventions followed by possible amelioration and 
prevention of serious sequelae (36). For the syndrome’s management, emphasis may be 
placed on lifestyle and symptom-directed treatment until future new discoveries.
The major strength of our study is in its population-based approach with a large sample size 
of women in three states undergoing ART in multiple years. Another important strength is 
the use of a linked file, NASS with live-birth certificates, which provided access to maternal 
characteristics as well as to pregnancy and newborn outcomes that are unavailable in NASS. 
Our study is also unique in that exposed and nonexposed groups were selected from the 
same cohort of women who underwent ART. More specific, women with TO provide an 
appropriate nonexposed group owing to their difference in hormone profiles compared with 
women with OD/PCOS and not in terms of fertility treatment, since women from both 
groups underwent ART. Thus the study findings mainly reflect the impact of the impaired 
hormone profile of PCOS (exposure) on maternal and pregnancy characteristics and 
furthermore on the selected outcomes of interest. To our knowledge, this study is the first to 
assess the impact of different infertility diagnoses, independently of ART, on pregnancy 
characteristics and outcomes by using the linked files created through the SMART 
collaborative.
There are, however, a few limitations to acknowledge. First, information about preexisting 
conditions and even gestation-related health issues could be incomplete in the live-birth 
records. For example, underreporting and thus missing values prevented us from exploring 
gestational diabetes separately. Second, we were not able to use the NICU admission rate in 
multivariate analysis since the information is not available in all three states. Nevertheless, 
our study findings from Florida and Michigan mirrored existing knowledge regarding the 
effects of PCOS on pregnancy outcomes and newborns’ health status shortly after birth (17). 
Another gap in the data that were available was the women’s weight, which is a known risk 
factor among women with PCOS that we were unable to account for due to a lack of data 
available in the live-birth files from all three states. Women with PCOS have an increased 
propensity towards OD in the presence of obesity, with anovulatory patients with PCOS 
having a greater body mass index than their ovulatory sisters, despite both siblings having 
ovarian hyperandrogenism (37, 38). Adverse outcomes in women with PCOS might be 
exacerbated by obesity.
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In conclusion, women/mothers with OD/PCOS who underwent ART have different maternal 
and pregnancy issues (high prevalence of diabetes) and offspring outcomes (lower Apgar 
score) compared with women with TO. Prevention strategies targeted towards improving the 
metabolic and endocrine consequences of OD/PCOS, such as changes in lifestyle, diet, and 
appropriate vitamin supplementation may optimize the health of women with the syndrome 
before conception (39–41). Assessing whether a woman has a family history of PCOS and 
evaluating her risks during pregnancy and postpartum as well as her newborn’s health status 
may lead to targeted prevention strategies that in turn may decrease both the health risks and 
economic burden of PCOS.
There is an increasing awareness that PCOS is a condition associated with an increased 
morbidity and long-term health problems beyond infertility (17). The population-based 
approach of our study adds value to the existing body of literature related to PCOS and 
warrants further consideration of public and private collaboration for better data collection 
and monitoring.
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TABLE 1
Maternal and pregnancy characteristics by specific infertility diagnosis (OD/PCOS and TO)—2000–2006 
NASS data linked with state live-birth records from Florida, Massachusetts, and Michigan.
OD/PCOS (only) TO (only)
n Percent (95% CI) n Percent (95% CI)
Total 1,433 100.0 (8.5% of 16,876) 3,294 100.0 (19.5% of 16,876)
Age
 <35 941 65.7 (62.7, 68.5) 1,611 48.9 (45.1, 52.7)
 ≥35 492 34.3 (31.5, 37.3) 1,683 51.1 (47.3, 54.9)
 Missing/unknowna 0 0
Race/ethnicity
 White 1,224 85.4 (80.6, 89.2) 2,451 74.4 (69.2, 79.0)
 Black 23 1.6 (1.1, 2.3) 281 8.5 (7.1, 10.2)
 Hispanic 76 5.3 (2.5,11.0) 374 11.4 (7.2, 17.4)
 Otherb 97 6.8 (5.4, 8.5) 160 4.9 (3.7, 6.3)
 Missing/unknowna 13 0.9 28 0.9
Education
 High school and less 151 10.5 (8.7, 12.7) 884 26.8 (24.2, 29.7)
 Some college/college graduate 854 59.6 (55.8, 63.3) 1,866 56.6 (54.5, 58.8)
 More than college 421 29.4 (26.5, 32.4) 514 15.6 (13.7, 17.7)
 Missing/unknowna 7 0.9 30 0.9
Adequacy of prenatal care
 Adequate+ 838 58.5 (55.7, 61.2) 1,839 55.8 (53.9, 57.7)
 Adequate 422 29.4 (26.5, 32.6) 1,039 31.5 (29.8, 33.3)
 Intermediate 80 5.6 (4.2, 7.4) 194 5.9 (4.5, 7.6)
 Inadequate 28 2.0 (1.4, 2.8) 67 2.0 (1.6, 2.5)
 Missing/unknowna 65 4.5 155 4.7
Comorbid conditionc
 Preexisting hypertension 449 31.3 (17.9, 48.9) 1,291 39.2 (22.3, 59.1)
 Gestational hypertension 481 33.6 (21.0, 49.0) 1,319 40.0 (24.3, 58.2)
 Diabetes (gestational and preexisting) 126 8.8 (6.7, 11.4) 176 5.3 (4.5, 6.4)
 Missing/unknowna 82 5.7 80 2.4
Plurality
 Singletons 929 64.8 (62.0, 67.6) 2,179 66.2 (63.7, 68.5)
 Twins 461 32.2 (29.8, 34.6) 1,021 31.0 (28.7, 33.4)
 ≥Triplets 43 3.0 (2.2, 4.0) 94 2.9 (2.2, 3.7)
 Missing/unknowna 0 0
Delivery method
 Vaginal 674 47.0 (43.7, 50.4) 1,545 46.9 (44.4–49.4)
 Cesarean section 754 52.6 (49.2, 56.0) 1,742 52.9 (50.4–55.4)
 Missing/unknowna 5 0.3 7 0.2
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OD/PCOS (only) TO (only)
n Percent (95% CI) n Percent (95% CI)
Labor induction
 Yes 193 13.5 (10.1, 17.7) 412 12.5 (10.5, 14.8)
 No 936 65.3 (57.1, 72.7) 2,039 61.9 (50.9, 71.8)
 Missing/unknowna 304 21.2 843 25.6
Note: Male infertility is not included.
a
We did not consider it necessary to provide the 95% CI for missing/unknown.
b
Massachusetts provided only four levels.
c
Not mutually exclusive and including only women with at least one of the comorbid conditions of interest.
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TABLE 3
Crude and adjusted ORsa of Apgar score below 7 in offspring of women with OD/PCOS versus those with TO
—2000–2006 NASS data linked with state live-birth records from Florida, Massachusetts, and Michigan.
cOR (95% CI) aORa (95% CI)
OD/PCOS 1.86 (1.31, 2.64) 1.90 (1.30, 2.77)
TO 1.0 1.0
a
We controlled for maternal age, race, education, adequacy of prenatal care per the Kotelchuck index, comorbidities (hypertension and diabetes), 
method of delivery (vaginal and cesarean section), labor induction, composite gestational age and birth weight as pregnancy outcome, and infant’s 
sex.
Fertil Steril. Author manuscript; available in PMC 2016 January 05.
